SGLT2 Inhibitor-Induced Ketonemia and Its Related Metabolic and Anti-Inflammatory Impacts in Adult Patients with Type 2 Diabetes SGLT2 inhibitor-induced ketonemia in type 2 diabetes
Iranian Journal of Pharmaceutical Sciences,
Vol. 19 No. 2 (2023),
1 April 2023
,
Page 176- 187
https://doi.org/10.22037/ijps.v19i2.42072
Abstract
Ketosis and attenuation of low-grade inflammation have been reported after consumption of sodium-glucose cotransporter-2 (SGLT2) inhibitors, but their mechanism and metabolic consequences have not been clearly defined. This clinical trial study aimed to assess SGLT2 inhibitor-induced ketonemia and its association with metabolic profiles and interleukin 6 (IL-6) levels in patients with type 2 diabetes mellitus (T2D). Biochemical variables, including fasting blood sugar (FBS), beta-hydroxybutyrate (BOBH), uric acid (UA), phosphate, insulin, glucagon, adrenocorticotropic hormone (ACTH), cortisol, and IL-6, were measured in 77 patients with T2D before and one month after treatment with empagliflozin (38 patients) and compared with a matched control group (39 patients). The patients in the intervention group received metformin and 10 mg empagliflozin, while those in the control group received metformin alone. The results revealed a significant decrease in IL-6, UA, FBS, glycated hemoglobin (HbA1C), body mass index (BMI), blood pressure, and the homeostasis model assessment–estimated insulin resistance (HOMA-IR) index after one month in the intervention group. However, the BOHB concentrations were significantly higher only in the empagliflozin recipients (p=0.040), with no symptoms or signs of ketoacidosis. Despite the increase in the concentration of BOHB, no significant difference was observed regarding insulin, glucagon, ACTH, and cortisol levels before and after taking empagliflozin. Besides, both groups observed a positive correlation between BOHB and UA levels (r=0.680, p=0.0001 in the empagliflozin group and r=0.646, p=0.002 in controls). Nevertheless, HOMA-IR and UA concentrations decreased significantly only in the intervention group (p=0.020 and p=0.011, respectively). At the end of the study, IL-6 levels showed a significant reduction within the groups and more in the intervention group compared to the controls. IL-6 levels were positively correlated to HOMA-IR (r=0.401, p=0.013) in the intervention group, but no relationship was detected between IL-6 and BMI, BOHB, UA, and insulin concentrations in the two groups. Based on the results, SGLT2 inhibitor-associated ketonemia was independent of changes in the insulin, glucagon, or cortisol levels. However, low-grade ketosis was associated with improved insulin sensitivity. The results also suggest that SGLT2 inhibitors possess anti-inflammatory activity, possibly mediated by their ability to reduce insulin resistance.
- Beta-hydroxybutyrate
- Empagliflozin
- Homeostasis model assessment–estimated insulin resistance index
- Interleukin 6
- Type 2 diabetes
- Uric acid
How to Cite
References
Firas Younis F, Jonathan Leor J, Zaid Abassi Z, Natalie Landa N, Lea Rath, Kenneth Hollander, Nili Naftali-Shani, Talma Rosenthal. Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat. J. Cardiovasc. Pharmacol. Ther (2018) 23 (4):358-371.
Fitchett D., Inzucchi S. E., Lachin J. M., Wanner C., van de Borne P., Mattheus M., Johansen O. E., et el. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J. Am. Coll. Cardiol (2018) 71 (3):364-367.
Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire DK, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINEHF trial. Circulation (2019) 140 (18):1463–147.
Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment with Sodium–Glucose Cotransporter 2 Inhibition. Diabetes. Care (2015) 38 (9):1687-1693.
Wang KM, Isom RT. SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report. Kidney. Med (2020) 2 (2): 218–221.
Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, et al. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients with Type 2 Diabetes. Diabetes (2016) 65 (5):1190-5.
Wanga MY, Yua X, Lee Y, McCorkleb SK , Chena S , Lic J, Wang ZV, et al. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes. Proc. Natl. Acad. Sci. U S A (2017) 114 (25):6611-6616.
Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl U C, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest (2014) 124 (2): 499–508.
Alatrach M, Laichuthai N, Martinez R, Agyin C, Ali AM, Al-Jobori H, Lavynenko O, et al. Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors. Diabetes (2020) 69 (4):681-688.
Herring RA, Shojaee-Moradie F, Garesse R, Stevenage M, Jackson N, Fielding BA, Mendis A, et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People with Type 1 Diabetes. Diabetes. Care (2020) 43 (9):2128-36.
Higashikawa T, Ito T, Mizuno T, Ishigami K, Kuroki K, Maekawa N, Usuda D, et al. Effects of tofogliflozin on adrenocorticotropic hormone, renin and aldosterone, and cortisol levels in elderly patients with diabetes mellitus: A retrospective study of a patient cohort. Medicine (Baltimore) (2021) 100 (45): e27638.
Min SH, Oh TJ, Baek SI, Lee DH, Kim KM, Moon JH, Choi SH, et al. Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes. Diabetes. Metab (2018) 44 (1):73-6.
Prattichizzo F, De Nigris V, Micheloni S, La Sala L, Ceriello A. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammatin the neglected component? Diabetes. Obes. Metab (2018) 20 (11):2515–2522.
Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes. Metab (2018) 44(6):457–464.
Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, Mayer G. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia (2019) 62 (7):1154–1166.
Garvey WT, Van Gaal L, Leiter LA, Vijapurkar U, List J, Cuddihy R, Ren J, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism (2018) 85:32–37.
Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, Tamai I. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm. Drug. Dispos (2014) 35 (7):391-404.
Ahmadieh H, Azar S. Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus. Diabetes. Technol. Ther (2017) 19 (9):507-512.
Bhole V, Choi JWJ, Kim SW, de Vera M, Choi H. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am. J. Med (2010) 123 (10):957-61.
Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes. Obes. Metab (2019) 21 (6):1291-8.
Packer M. Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials with Allopurinol and SGLT2 Inhibitors. J. Card. Fail (2020) 26 (11):977-84.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T , Hou FF, Mann JFE, et al. DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med (2020) 383 (15):1436–1446.
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, et al. DAPAHF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med (2019) 381(21):1995–2008.
Ekanayake P, Mudaliar S. A novel hypothesis linking low-grade ketonaemia to cardio-renal benefits with sodium-glucose cotransporter-2 inhibitors. Diabetes. Obes. Metab (2022) 24 (1):3-11.
Mudaliar S, Hupfeld C, Chao DL. SGLT2 Inhibitor–Induced Low-Grade Ketonemia Ameliorates Retinal Hypoxia in Diabetic Retinopathy—A Novel Hypothesis. J. Clin. Endocrinol. Metab (2021) 106 (5):1235-1244.
Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, Rim JH, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat. Commun (2020) 11 (1):2127.
Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest (2014) 124 (2):509-14.
Kuhre RE, Ghiasi SM, Adriaenssens AE, Albrechtsen NJW, Andersen DB, Aivazidis A, Chen L, et al. No direct effect of SGLT2 activity on glucagon secretion. Diabetologia (2019) 62 (6):1011–1023.
Capozzi ME, Coch RW, Koech J, Astapova II, Wait JB, Encisco SE, Douros JD, et al. The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition. Diabetes (2020) 69 (5): 882–892.
Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: part 2. Antidiabetic effects in type 2 diabetic mice. J. Pharmacol. Sci (2016) 131 (3):198–208.
Hosokawa Y, Ogawa W. SGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical use. J. Diabetes. Investig (2020) 11 (6):1431-3.
Huet C, Boudaba N, Guigas B, Viollet B, Marc Foretz M. Glucose availability but not changes in pancreatic hormones sensitizes hepatic AMPK activity during nutritional transition in rodents. J. Biol. Chem (2020) 295 (18): 5836–5849.
Perry RJ, Rabin-Court A, Song JD, Cardone RL, Wang Y, Kibbey R G, Shulman GI. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor treated rats. Nat. Commun (2019) 10 (1):548.
Yu P, Huang L, Wang Z, Meng X, Yu X. The Association of Serum Uric Acid with Beta-Cell Function and Insulin Resistance in Nondiabetic Individuals: A Cross-Sectional Study. Diabetes. Metab. Syndr. Obes (2021) 14:2673-82.
Huttl M, Markova I, Miklankova D, Oliyarnyk O, Trnovska J, Kucera J, Sedlacek R, et al. Metabolic cardio- and reno-protective effects of empagliflozin in a prediabetic rat model. J. Physiol. Pharmacol (2020) 71 (5).
Kullmann S, Hummel J, Wagner R, Dannecker C, Vosseler A, Fritsche L, Veit R, et al. Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial. Diabetes. Care (2022) 45(2):398–406.
Shimobayashi M, Albert V, Woelnerhanssen B, Frei IC, Weissenberger D, Meyer-Gerspach AC, Clement N, et al. Insulin resistance causes inflammation in adipose tissue. J. Clin. Invest (2018) 128 (4):1538-1550.
Rau M, Thiele K, Hartmann NUK, Möllmann J, Wied S, Hohl M, Marx N, et al. Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes - Data from a randomized, placebo-controlled study. Bone. Rep (2022) 16:101175.
- Abstract Viewed: 484 times
- IJPS_Volume19_Issue2-Pages 176-187 Downloaded: 391 times